Copyright
©The Author(s) 2017.
World J Diabetes. Jul 15, 2017; 8(7): 311-316
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.311
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.311
Figure 2 The role of proprotein convertase subtilisin/kexin type 9 on carbohydrate homeostasis.
Accordingly, PCSK9 inhibitors may be associated with a neutral effect on carbohydrate homeostasis at least in the short term. PCSK9: Proprotein convertase subtilisin/kexin type 9; LDL: Low-density lipoprotein; LDLR: LDL receptors; HbA1c: Glycated hemoglobin; SREBP-1C: Sterol regulatory element-binding protein I-C; HOMA-IR: Homeostasis model assessment-insulin resistance.
- Citation: Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. PCSK9 and carbohydrate metabolism: A double-edged sword. World J Diabetes 2017; 8(7): 311-316
- URL: https://www.wjgnet.com/1948-9358/full/v8/i7/311.htm
- DOI: https://dx.doi.org/10.4239/wjd.v8.i7.311